719 related articles for article (PubMed ID: 26118503)
21. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
22. The emerging roles of DOT1L in leukemia and normal development.
McLean CM; Karemaker ID; van Leeuwen F
Leukemia; 2014 Nov; 28(11):2131-8. PubMed ID: 24854991
[TBL] [Abstract][Full Text] [Related]
23. Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases.
Chopra M; Bohlander SK
Cancer Genet; 2015 May; 208(5):192-205. PubMed ID: 25592767
[TBL] [Abstract][Full Text] [Related]
24. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
25. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
26. A higher-order configuration of the heterodimeric DOT1L-AF10 coiled-coil domains potentiates their leukemogenenic activity.
Song X; Yang L; Wang M; Gu Y; Ye B; Fan Z; Xu RM; Yang N
Proc Natl Acad Sci U S A; 2019 Oct; 116(40):19917-19923. PubMed ID: 31527241
[TBL] [Abstract][Full Text] [Related]
27. DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation.
Song T; Zou Q; Yan Y; Lv S; Li N; Zhao X; Ma X; Liu H; Tang B; Sun L
Cell Rep; 2021 Sep; 36(12):109739. PubMed ID: 34551297
[TBL] [Abstract][Full Text] [Related]
28. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
29. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
30. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
31. Disordered epigenetic regulation in MLL-related leukemia.
Zhang Y; Chen A; Yan XM; Huang G
Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
[TBL] [Abstract][Full Text] [Related]
32. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
33. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
35. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
[TBL] [Abstract][Full Text] [Related]
36. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
[TBL] [Abstract][Full Text] [Related]
37. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
[TBL] [Abstract][Full Text] [Related]
38. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
[TBL] [Abstract][Full Text] [Related]
39. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
40. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
Jo SY; Granowicz EM; Maillard I; Thomas D; Hess JL
Blood; 2011 May; 117(18):4759-68. PubMed ID: 21398221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]